Patents Assigned to Orexigen Therapeutics, Inc.
-
Patent number: 9801875Abstract: The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes.Type: GrantFiled: August 28, 2015Date of Patent: October 31, 2017Assignee: Orexigen Therapeutics, Inc.Inventors: Preston Klassen, Kristin Taylor
-
Patent number: 9633575Abstract: The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.Type: GrantFiled: June 5, 2013Date of Patent: April 25, 2017Assignee: Orexigen Therapeutics, Inc.Inventors: Preston Klassen, Kristin Taylor
-
Patent number: 9457005Abstract: Methods and compositions for treating a blood glucose condition involve identifying a suitable subject and administering an effective amount of a composition that contains one or more of an opioid antagonist, an anticonvulsant, and a psychotherapeutic agent. The compositions can include insulin. In some embodiments, such methods and compositions can be used to modulate a blood glucose level. In preferred embodiments, such methods and compositions are useful for increasing a subject's sensitivity to insulin.Type: GrantFiled: July 8, 2014Date of Patent: October 4, 2016Assignee: OREXIGEN THERAPEUTICS, INC.Inventors: Michael A. Cowley, Anthony A. McKinney, Gary Tollefson
-
Patent number: 9248123Abstract: Disclosed are methods of providing weight loss therapy, particularly for patients suffering from major depression.Type: GrantFiled: January 10, 2011Date of Patent: February 2, 2016Assignee: Orexigen Therapeutics, Inc.Inventors: Eduardo Dunayevich, Gary Tollefson, David Dewitt
-
Patent number: 9125868Abstract: Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.Type: GrantFiled: March 20, 2014Date of Patent: September 8, 2015Assignee: OREXIGEN THERAPEUTICS, INC.Inventors: Anthony A. McKinney, Gary Tollefson, Eckard Weber, Rick Soltero
-
Patent number: 9119850Abstract: The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes.Type: GrantFiled: March 2, 2015Date of Patent: September 1, 2015Assignee: Orexigen Therapeutics, Inc.Inventors: Preston Klassen, Kristin Taylor
-
Patent number: 9107837Abstract: A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition.Type: GrantFiled: November 26, 2014Date of Patent: August 18, 2015Assignee: Orexigen Therapeutics, Inc.Inventors: Anthony A. McKinney, Gary D. Tollefson, Richard Soltero, Thea Elise Dunzo
-
Patent number: 8969371Abstract: The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes.Type: GrantFiled: July 2, 2014Date of Patent: March 3, 2015Assignee: Orexigen Therapeutics, Inc.Inventors: Preston Klassen, Kristin Taylor
-
Patent number: 8916195Abstract: A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition.Type: GrantFiled: June 4, 2007Date of Patent: December 23, 2014Assignee: Orexigen Therapeutics, Inc.Inventors: Anthony A. McKinney, Gary D. Tollefson, Richard Soltero, Thea Elise Dunzo
-
Patent number: 8815889Abstract: Methods and compositions for treating a blood glucose condition involve identifying a suitable subject and administering an effective amount of a composition that contains one or more of an opioid antagonist, an anticonvulsant, and a psychotherapeutic agent. The compositions can include insulin. In some embodiments, such methods and compositions can be used to modulate a blood glucose level. In preferred embodiments, such methods and compositions are useful for increasing a subject's sensitivity to insulin.Type: GrantFiled: November 21, 2006Date of Patent: August 26, 2014Assignee: Orexigen Therapeutics, Inc.Inventors: Michael A. Cowley, Anthony A. McKinney, Gary Tollefson
-
Patent number: 8722085Abstract: Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.Type: GrantFiled: July 16, 2010Date of Patent: May 13, 2014Assignee: Orexigen Therapeutics, Inc.Inventors: Anthony McKinney, Gary Tollefson, Eckard Weber, Rick Soltero
-
Publication number: 20140080857Abstract: Pharmaceutical formulations comprise sustained-release zonisamide. Methods of preparing such pharmaceutical formulations involve intermixing zonisamide with a suitable excipient configured to control the dissolution profile of the zonisamide. Methods of treatment involve administering the pharmaceutical formulations to patients in need of such treatment.Type: ApplicationFiled: August 13, 2013Publication date: March 20, 2014Applicant: Orexigen Therapeutics, Inc.Inventors: Anthony A. McKinney, Gary Tollefson, Simon Kwok-Pan Yau, Ronald S. Vladyka, Rick Soltero
-
Publication number: 20130252995Abstract: Compositions, uses, kits and methods for reducing binge or compulsive eating are described herein. Methods may include administering an effective combination of a dosage of a bupropion or a pharmaceutically acceptable salt thereof, and a dosage of naltrexone or a pharmaceutically acceptable salt thereof. Methods may include identifying a patient who is overweight or obese and providing an effective combination of bupropion and naltrexone to the patient. Methods may include reducing a number of binge or compulsive eating events. Methods may include reducing severity of binge or compulsive eating events.Type: ApplicationFiled: December 2, 2011Publication date: September 26, 2013Applicant: OREXIGEN THERAPEUTICS, INC.Inventors: Eduardo Dunayevich, Susan Mcelroy, Ron Landbloom
-
Publication number: 20130245056Abstract: Disclosed are compositions, uses, methods and kits for increasing drug bioavailability in a naltrexone therapy.Type: ApplicationFiled: December 2, 2011Publication date: September 19, 2013Applicant: Orexigen Therapeutics, Inc.Inventors: Shawn Flanagan, Eduardo Dunayevich
-
Publication number: 20130177602Abstract: In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine.Type: ApplicationFiled: November 19, 2012Publication date: July 11, 2013Applicant: OREXIGEN THERAPEUTICS, INC.Inventor: Orexigen Therapeutics, Inc.
-
Patent number: 8318788Abstract: In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine.Type: GrantFiled: December 19, 2011Date of Patent: November 27, 2012Assignee: Orexigen Therapeutics, Inc.Inventors: Anthony McKinney, Gary Tollefson, Eckard Weber, Rick Soltero
-
Publication number: 20120093889Abstract: In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine.Type: ApplicationFiled: December 19, 2011Publication date: April 19, 2012Applicant: OREXIGEN THERAPEUTICS, INC.Inventors: Anthony McKinney, Gary Tollefson, Eckard Weber, Rick Soltero
-
Publication number: 20120010232Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.Type: ApplicationFiled: September 22, 2011Publication date: January 12, 2012Applicant: Orexigen Therapeutics, Inc.Inventors: Eckard Weber, Michael Alexander Cowley
-
Patent number: 8088786Abstract: In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine.Type: GrantFiled: November 8, 2007Date of Patent: January 3, 2012Assignee: Orexigen Therapeutics, Inc.Inventors: Anthony McKinney, Gary Tollefson, Eckard Weber, Rick Soltero
-
Publication number: 20110172260Abstract: Disclosed are methods of providing weight loss therapy, particularly for patients suffering from major depression.Type: ApplicationFiled: January 10, 2011Publication date: July 14, 2011Applicant: Orexigen Therapeutics, Inc.Inventors: Eduardo Dunayevich, Gary Tollefson, David Dewitt